Atrin Pharmaceuticals is a private biopharmaceutical company pioneering the discovery & development of proprietary molecules targeting DNA Damage and Response (DDR) pathways to treat a broad spectrum of cancers associated with synthetic lethality and the deregulated DNA Damage Response.